Name

Dr. Abidi Pharmaceuticals

Legal name

داروسازی دکتر عبیدی (Dr. Abidi Pharmaceuticals)

Website

https://abidipharma.com

Company type

Public

Founded year

1946

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales: Dr. Abidi Pharmaceuticals generates revenue through the manufacture and sale of prescription and OTC pharmaceutical products across 14 therapeutic areas, distributed through pharmacies across Iran. The company also produces licensed products under Sanofi (Plavix, Depakine).

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Dr. Abidi Pharmaceuticals manufactures and distributes prescription pharmaceuticals and OTC nutraceutical supplements across 14 therapeutic areas — cardiovascular, diabetes, neurology, oncology, allergy, gastroenterology, infectious diseases, respiratory, pain, psychiatry, urology/nephrology, pediatrics, obesity, and vitamins/supplements. The company also produces licensed products under Sanofi (Plavix, Depakine) and holds exclusive Iranian rights to AminoUp's AHCC Pro (marketed as Noaxa). Products are sold through a nationwide pharmacy network across Iran with prices regulated by Iran's Food and Drug Organization.

Product overview

Dr. Abidi Pharmaceuticals operates as a comprehensive pharmaceutical company offering both prescription medications and nutraceutical supplements. The product portfolio spans 14 therapeutic areas including cardiovascular diseases, diabetes, neurology, oncology, infectious diseases, gastroenterology, allergy/immunology, respiratory, pain management, psychiatry, urology/nephrology, obesity, pediatrics, and vitamins/supplements. The prescription portfolio includes branded pharmaceuticals such as Ropixon-Plus for lipid management, Ziveria for allergies, Phorize for reflux, and licensed products from Sanofi (Plavix, Depakin). The nutraceutical line includes bone health supplements (Bonarco, Bonarco Citrate), iron supplements (Ferrofort Energy), folate supplements (Revofolic line), and Noaxa for immune support.

Differentiator

Problem solved

Functional benefit

Brands

• Ziveria (زیوریا): Second-generation antihistamine product for allergy treatment containing Bilastine, launched during the company's 80th anniversary
• Ropixon (روپیکسون)
• Bonarco (بون‌آرکو)
• Betalief (بتالیف)
• Noaxa (نواکسا)
• Frofort (فروفورت)

Products and services

• Ropixon-Plus (روپیکسون-پلاس) Oral prescription medication for reducing blood lipids (cholesterol), positioned as the newest lipid-lowering solution following 10 years of market leadership with the original Ropixon product. Targeted at patients with cardiovascular and lipid management needs.
• Bonarco Citrate (بون‌آرکو سیترات) Calcium citrate and vitamin D3 nutraceutical supplement for bone health, designed for prevention and adjunct treatment of osteoporosis with high calcium absorption and gastrointestinal tolerance. Available without prescription at pharmacies.
• Bonarco (بون‌آرکو) Calcium supplement containing calcium, vitamin D3, and vitamin K2 in tablet form, supporting bone health and calcium absorption for osteoporosis prevention.
• Betalief (بتالیف) Over-the-counter pharmaceutical for fast-acting and sustained treatment of gastroesophageal reflux symptoms including heartburn and indigestion.
• Ziveria (زیوریا) Prescription second-generation antihistamine containing bilastine, used for allergic rhinitis and other allergic conditions, with minimal drowsiness compared to first-generation antihistamines.
• Noaxa (نواکسا) AHCC Pro nutraceutical supplement containing 20% alphaglucan, the only AHCC Professional available in Iran, designed to support HPV clearance by enhancing immune function; clinically demonstrated negative HPV test results after 6 months of use.
• Ferrofort Energy (فروفورت انرژی) Iron supplement containing ferrous bisglycinate, folic acid, vitamin C, vitamin B12, and zinc sulfate; formulated for iron deficiency and anemia with high gastrointestinal tolerability.
• Revofolic Regular (روفولیک رگولار) Folate supplement containing calcium L-methylfolate and vitamin B12, supporting general folate supplementation.
• Revofolic Prenatal (روفولیک پریناتال) Prenatal folate and iodine supplement containing calcium L-methylfolate and potassium iodide, designed for prenatal care.
• Revofolic Max (روفولیک مکس) High-dose folate supplement containing 1000 mcg calcium L-methylfolate and 50 mcg vitamin B12.
• Plavix (پلاویکس) Antiplatelet prescription medication (clopidogrel) produced under Sanofi license for cardiovascular protection in the Iranian market.
• Depakin (دپاکین) Anticonvulsant and mood stabilizer (sodium valproate) produced under Sanofi license for the Iranian market.
• Phorize (فورایز) P-CAB (Potassium-competitive acid blocker) prescription pharmaceutical for gastroesophageal reflux and H. pylori treatment, representing a newer class of acid suppression medication; available by prescription through pharmacies.
• Zcorpa (زیکورپا) GLP-1 receptor agonist prescription medication for obesity treatment, representing the company's first step into providing Iranian patients access to innovative obesity therapies.

Quantifiable outcome

• Over 10 million patients benefit from Dr. Abidi's therapeutic solutions
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• AminoUp (Japan)coreStrategic or Co-development PartnerAminoUp Co. Ltd., based in Japan, is the world's sole manufacturer of AHCC (Active Hexose Correlated Compound). The company has exclusively granted Dr. Abidi Pharmaceuticals the right to produce and market AHCC Pro in Iran under the brand Noaxa. This is the only AHCC Professional available in the Iranian market.
• Cobel Group (گروه کوبل)coreStrategic or Co-development PartnerDr. Abidi Pharmaceuticals is a member of Cobel Group, a large private Iranian pharmaceutical group with over 4,000 colleagues and 80 national brands. Cobel Group's subsidiary companies include Cobel Darou, Dr. Abidi Pharmaceuticals, and AdoraTeb. The group manages a complete integrated pharmaceutical cycle.
• Behvazan Pharmaceutical (داروسازی بهوزان)coreOthersBehvazan Pharmaceutical is a subsidiary of Dr. Abidi Pharmaceuticals. Its quality control laboratory received accreditation from Iran's Food and Drug Organization. Behvazan underwent financial and quality rehabilitation under investment from Cobel Group and Dr. Abidi Pharmaceuticals, developing modern infrastructure.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Darou Pakhsh Pharmaceutical: Iran's largest domestic pharmaceutical manufacturer, producing branded generics and specialty drugs across multiple therapeutic areas, distributing through pharmacies nationwide. Most direct Iranian competitor to Dr. Abidi given comparable portfolio breadth and channel model.
• TPICO (Tehran Pharma): Iranian pharma manufacturer with a diversified therapeutic-area portfolio and nationwide pharmacy distribution, similar to Dr. Abidi's multi-area model. Competes directly for retail shelf space and physician prescriptions in Iran.
• Sobhan Oncology: Iranian specialty pharmaceutical company focused on oncology and hematology products, distributing in Iran through hospital and pharmacy channels. Comparable as an Iranian listed pharma with branded specialty drug focus, albeit narrower in therapeutic breadth.
• Cobel Darou: Sister company of Dr. Abidi within Cobel Group, manufacturing branded pharmaceutical products for the Iranian market across overlapping therapeutic areas. Operates through the same Cobel distribution platform, making it the closest in-group peer.
• Tofigh Darou: Iranian pharmaceutical manufacturer with a diversified branded portfolio across cardiovascular, infectious diseases, and supplements. Operates through the same physician-pharmacy prescription model in Iran.
• Osvah Pharmaceutical: Iranian pharmaceutical manufacturer producing prescription and OTC products across multiple therapeutic areas with nationwide pharmacy distribution. Direct peer based on product mix, scale, and Iranian domestic market focus.
• Barakat Pharmaceutical (Darou Salamat): Large Iranian pharmaceutical manufacturer with a broad branded-generic portfolio distributed through pharmacies. State-linked entity serving comparable patient and physician segments to Dr. Abidi across multiple therapeutic areas.
• Loghman Pharmaceuticals: Iranian pharmaceutical manufacturer producing branded prescription drugs, OTCs, and supplements distributed through pharmacies. Overlapping portfolio across cardiovascular, respiratory, and supplement categories makes it a direct domestic comparable.

Broad incumbents

• Sanofi: Global pharmaceutical major and Dr. Abidi's licensing partner since 2009. Comparable as the originator of Plavix and Depakine, and as a broad incumbent whose specialty-care, cardiometabolic, and immunology franchises overlap with Dr. Abidi's stronger therapeutic areas.
• STADA Arzneimittel: European mid-size private pharmaceutical company with a branded-generic and consumer health portfolio across multiple therapeutic areas. Comparable to Dr. Abidi's combination of branded prescription drugs plus a growing nutraceutical/OTC supplement line.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/abidipharma

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dr. Abidi Pharmaceuticals